Skip to main content
Premium Trial:

Request an Annual Quote

New England Biolabs, Bluebee Partner for Sequencing Data Analysis

NEW YORK (GenomeWeb) – New England Biolabs and Netherlands-based bioinformatics firm Bluebee have formed a partnership to provide data processing of sequencing technology.

The partnership will allow customers using the NEBNext Direct workflow to rapidly analyze, store, and manage large amounts of sequencing data using a pipeline designed by Bluebee to maximize the benefits of the target enrichment technology. NEBNext Direct is a workflow that hybridizes baits directly to genomic DNA without the need for upfront library preparation and incorporates a unique molecule index to improve accuracy of predictions of variant allele frequencies.

NEBNext Direct has also been added by the firm into the NEBNext Direct Cancer HotSpot Panel, which provides a one-day, single-tube workflow combining enrichment with library preparation and enriching critical regions within 50 commonly studied genes known to be associated with cancer.

"Having the ability to execute complex analytical procedures through a simple user interface ensures our customers reliable and accurate data, providing them more time to analyze and interpret results," Andrew Barry, product marketing manager at NEB, said in a statement.

The Bluebee platform supports users in clinical diagnostics, therapeutics, and research with analytics for genomic medicine through a private cloud service. It centralizes and manages genomics data processes and storage, with multi-layered security to meet both organizational and regulatory data protection requirements.

Bluebee raised €10 million ($11.6 million) in a Series A financing round in 2016, and has since formed partnerships with firms such as GATC Biotech, Lexogen, MediSapiens, Pacific Biosciences, and Agendia.  

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more